The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study
Open Access
- 1 May 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (5) , 633-641
- https://doi.org/10.1023/a:1011102619058
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinomaAnnals of Oncology, 1999
- Management of Cancer of the ProstateNew England Journal of Medicine, 1994
- Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical careCancer, 1994
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- The influence of cancer patients' symptoms and functional states on patients' depression and family caregivers' reaction and depression.Health Psychology, 1993
- Cancer pain in the marital system: A study of patients and their spousesJournal of Pain and Symptom Management, 1992
- Psychological adaptation to cancer: A comparison among patients, spouses, and nonspouses.Family Systems Medicine, 1988
- A psychological analysis of cancer patients and their next-of-kinCancer, 1985